FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3178177832> ?p ?o ?g. }

• W3178177832 abstract "Chimeric antigen receptor modified T cells (CAR T) have demonstrated remarkable clinical efficacy in the treatment of B cell malignancies and multiple myeloma. Significant challenges restrict their application across solid tumors due to multiple obstacles, including the lack of robust in vivo CAR-T cell expansion and persistence, the immunosuppressive tumor microenvironment.To address these difficulties, we generated CAR T cells using a novel CoupledCAR® technology. Specifically, we engineered CoupledCAR T cells with lentiviral vectors encoding an anti-thyroid stimulating hormone receptor (TSHR) CAR molecule. Immunohistochemistry (IHC) results showed that TSHR was highly expressed in thyroid cancer cells making it an ideal tumor-specific target antigen. In vitro co-culture experiments showed that TSHR CAR T cells specifically recognized and subsequently killed TSHR-positive tumor cells. Animal model experiments showed that TSHR CAR T cells inhibited the proliferation of TSHR-positive tumor cells.To evaluate the clinical safety and efficacy of anti-TSHR CoupledCAR T cells on refractory or relapsed thyroid cancer, we treated refractory/relapsed post-thyroidectomy thyroid cancer patients according to an IRB approved protocol. We treated two patients using anti-TSHR CoupledCAR T cells and observed the rapid expansion of CAR T cells and enhanced the killing of tumor cells. One patient's best response was complete remission, and the other was near complete remission.Patient 1 Male, 64Y, Papillary Thyroid Carcinoma. In May 2017, Thyroid cancer was diagnosed, bilateral total thyroidectomy, and right cervical lymph node functional dissection were performed in Jun 2018, followed by iodine 131 isotope therapy. In December 2018, bilateral multiple cervical lymph nodes were enlarged, especially on the right side. In February 2019, right neck lymphadenectomy was performed.Patient 2 Female, 60Y, Thyroid Carcinoma. In Aug 2013, a double lobectomy of the thyroid gland” was performed. From Oct 2013 to Jan 2014, she received iodine 131 isotope therapy. In Sep 2014, she was diagnosed with iodine - resistant thyroid cancer. From Sep to Jan 2016, 5 cycles of chemotherapy were performed. In Jun 2016, she enrolled in the Anlotinib experimental group. In Mar 2019, multiple metastases in both lungs and multiple enlarged lymph nodes in the mediastinum were observed.Patient 1: One month after infusion (M1), the patient was evaluated as PR. Three months after infusion (M3), the patient was evaluated as CR, and the patient's CR lasted from M3 to M12 after infused anti-TSHR CoupledCAR T cells , and we are still following up.Patient 2: M1, the patient was evaluated as PR (Partial Response): the tumor volume in the right lower lobe of the lung was reduced by approximately 67.51% (decreased from 65*55mm to 42*39mm). Three months after infusion (M3), compared with that before, the tumor volume was reduced by approximately 73.54% and SUV max value decreased from 14.9 to 2.8, therefore, the patient was evaluated as nCR (near complete remission).We show that TSHR is a good target for treating thyroid cancer, and our anti-TSHR CoupledCAR T cells are safe and effective for treating thyroid cancer. Recruitment is ongoing to evaluate the safety and efficacy of our CoupledCAR T cells. Further, since our CoupledCAR® technology is a platform technology, we are developing it to treat other solid tumors using different target tumor markers.Citation Format: Lei Xiao, Xingchen Liu, Keshu Zhou, Yu Liu, Yong Huang, Chengfei Pu, Zhiyuan Cao, Ruihong Zhu, Haiyang Tang, Zhipeng Huang, Hang Yang, Xi Huang, Yongping Song, Renbin Liu, Zhao Wu, Victor Lu. CoupledCARTMtechnology for treating thyroid cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr LB145." @default.
• W3178177832 created "2021-07-19" @default.
• W3178177832 creator A5000406804 @default.
• W3178177832 creator A5004497219 @default.
• W3178177832 creator A5008514827 @default.
• W3178177832 creator A5013345301 @default.
• W3178177832 creator A5018073672 @default.
• W3178177832 creator A5022298216 @default.
• W3178177832 creator A5024165645 @default.
• W3178177832 creator A5026012257 @default.
• W3178177832 creator A5030354203 @default.
• W3178177832 creator A5038510476 @default.
• W3178177832 creator A5050298825 @default.
• W3178177832 creator A5050450526 @default.
• W3178177832 creator A5060969271 @default.
• W3178177832 creator A5070396578 @default.
• W3178177832 creator A5072208080 @default.
• W3178177832 creator A5080780412 @default.
• W3178177832 date "2021-07-01" @default.
• W3178177832 modified "2023-10-16" @default.
• W3178177832 title "Abstract LB145: CoupledCARTMtechnology for treating thyroid cancer" @default.
• W3178177832 doi "https://doi.org/10.1158/1538-7445.am2021-lb145" @default.
• W3178177832 hasPublicationYear "2021" @default.
• W3178177832 type Work @default.
• W3178177832 sameAs 3178177832 @default.
• W3178177832 citedByCount "0" @default.
• W3178177832 crossrefType "proceedings-article" @default.
• W3178177832 hasAuthorship W3178177832A5000406804 @default.
• W3178177832 hasAuthorship W3178177832A5004497219 @default.
• W3178177832 hasAuthorship W3178177832A5008514827 @default.
• W3178177832 hasAuthorship W3178177832A5013345301 @default.
• W3178177832 hasAuthorship W3178177832A5018073672 @default.
• W3178177832 hasAuthorship W3178177832A5022298216 @default.
• W3178177832 hasAuthorship W3178177832A5024165645 @default.
• W3178177832 hasAuthorship W3178177832A5026012257 @default.
• W3178177832 hasAuthorship W3178177832A5030354203 @default.
• W3178177832 hasAuthorship W3178177832A5038510476 @default.
• W3178177832 hasAuthorship W3178177832A5050298825 @default.
• W3178177832 hasAuthorship W3178177832A5050450526 @default.
• W3178177832 hasAuthorship W3178177832A5060969271 @default.
• W3178177832 hasAuthorship W3178177832A5070396578 @default.
• W3178177832 hasAuthorship W3178177832A5072208080 @default.
• W3178177832 hasAuthorship W3178177832A5080780412 @default.
• W3178177832 hasConcept C121608353 @default.
• W3178177832 hasConcept C126322002 @default.
• W3178177832 hasConcept C142724271 @default.
• W3178177832 hasConcept C143998085 @default.
• W3178177832 hasConcept C147483822 @default.
• W3178177832 hasConcept C203014093 @default.
• W3178177832 hasConcept C2777701055 @default.
• W3178177832 hasConcept C2779761222 @default.
• W3178177832 hasConcept C2780849966 @default.
• W3178177832 hasConcept C2781461381 @default.
• W3178177832 hasConcept C3875195 @default.
• W3178177832 hasConcept C502942594 @default.
• W3178177832 hasConcept C526584372 @default.
• W3178177832 hasConcept C71924100 @default.
• W3178177832 hasConceptScore W3178177832C121608353 @default.
• W3178177832 hasConceptScore W3178177832C126322002 @default.
• W3178177832 hasConceptScore W3178177832C142724271 @default.
• W3178177832 hasConceptScore W3178177832C143998085 @default.
• W3178177832 hasConceptScore W3178177832C147483822 @default.
• W3178177832 hasConceptScore W3178177832C203014093 @default.
• W3178177832 hasConceptScore W3178177832C2777701055 @default.
• W3178177832 hasConceptScore W3178177832C2779761222 @default.
• W3178177832 hasConceptScore W3178177832C2780849966 @default.
• W3178177832 hasConceptScore W3178177832C2781461381 @default.
• W3178177832 hasConceptScore W3178177832C3875195 @default.
• W3178177832 hasConceptScore W3178177832C502942594 @default.
• W3178177832 hasConceptScore W3178177832C526584372 @default.
• W3178177832 hasConceptScore W3178177832C71924100 @default.
• W3178177832 hasLocation W31781778321 @default.
• W3178177832 hasOpenAccess W3178177832 @default.
• W3178177832 hasPrimaryLocation W31781778321 @default.
• W3178177832 hasRelatedWork W1527810004 @default.
• W3178177832 hasRelatedWork W2028411003 @default.
• W3178177832 hasRelatedWork W2075647934 @default.
• W3178177832 hasRelatedWork W2092948006 @default.
• W3178177832 hasRelatedWork W2097280954 @default.
• W3178177832 hasRelatedWork W2792279180 @default.
• W3178177832 hasRelatedWork W2956005636 @default.
• W3178177832 hasRelatedWork W2976515815 @default.
• W3178177832 hasRelatedWork W3022228189 @default.
• W3178177832 hasRelatedWork W3197851477 @default.
• W3178177832 isParatext "false" @default.
• W3178177832 isRetracted "false" @default.
• W3178177832 magId "3178177832" @default.
• W3178177832 workType "article" @default.